GENEROUS Changes Everything: How the New CMS MFN Model Is Reshaping U.S. Drug Pricing in 2025–2026
What began as “Most Favored Nation” (MFN) concepts has now materialized into concrete policy mechanisms.
What began as “Most Favored Nation” (MFN) concepts has now materialized into concrete policy mechanisms.
The EU Health Technology Assessment Regulation (HTAR) represents one of the most significant shifts in
In 2023, U.S. retail prescription drug market value grew 11.4% to $449.7B, about 9% of
The Italian Medicines Agency has published their annual AIFA Activity Report in 2025, outlining the
As U.S. trade policy tightens, pharmaceutical and biotech companies face a pivotal strategic question: does
Germany: Europe’s Largest Pharma Market Germany is one of the key focus markets for pharma,